Ute to tumour improvement not only by means of SASP but also exosomes through aging process. Summary/Conclusion: Here we show a novel function of exosomes secreted from senescent cells on chromosomal instability. These data suggest that senescenceassociated exosome secretion may possibly contribute to agerelated increase of cancer incidence. Funding: PRESTO, JST.OF15.Orthotopic neuroblastoma tumour model creating CD314/NKG2D Proteins Accession GFP-labelled extracellular vesicles (EV) reveals certain capture of GPF EV by monocytes/macrophages and mesenchymal cells in liver and bone marrow Yves A. DeClercka, Laurence Blavierb and Rie Nakataca University of Southern California, Los Angeles, CA, USA; bChildren’s Hospital Los Angeles, LosAngeles, CA, USA; cChildren’s Hospital Los Angeles, Los Angeles, CA, USAResults: Preliminary experiments with PKH67-stained NB-derived EV injected i.v. showed that right after 24 h 0.91 of CD 45+cells in the BM, six.70.3 of CD105 + cells in the bone, and 0.2.two of CD45+ in the liver and lung contained green vesicles. In mice orthotopically implanted with NB cells creating GFP-labelled EV, we observed an increasing volume of GD2- /GFP+ cells in the BM (0.two) involving week 2 and six. The expression of CD45, CD11b, and CD105 in these GD2- cells suggests their myeloid, monocytic, and mesenchymal origin. In the liver, a related capture by CD45+ and CD11b+ was observed (up to 0.two). We also observed an growing quantity of GD2- /GFP+ cells that were damaging for CD45, CD11b, and CD105 at week 6. No GFP+ cells have been detected in the lung, spleen and kidney. Summary/Conclusion: Tumour-derived exosomes are especially captured by a compact percentage (inside the limits of FACS detection) of myeloid and stromal cells in the BM and the liver Metabotropic Glutamate Receptors Proteins Purity & Documentation within the early stages of tumour improvement ahead of NB cells home to these organs. The data which used an orthotopic model rather i.v. injection, help the notion that exosomes contribute towards the pre-metastatic niche. Funding: RO1 CA 207983 in the National Institutes of Health, USA.OF15.ExoBow a transgenic tactic to study CD63+extracellular vesicles in vivo B bara Adema, Nuno Bastosa, Carolina Ruivoa, Maxwell Goodrichb, Zhang Xiaojingc, Barbara Seidlerd, David W Goodriche, Jose L Costaf, JosMachadof, Dieter Saurg, Dawen Caih and S ia Melof i3S Instituto de Investiga o e Inova o em Sa e, Porto University, Portugal; IPATIMUP Instituto de Patologia e Imunologia Molecular da Universidade do Porto; ICBAS Instituto de Ci cias Biom icas Abel Salazar da Universidade do Porto, Porto, Portugal; bDepartment of Pharmacology Therapeutics, Roswell Park Extensive Cancer Center, New york, NY, USA; 34Department of Pharmacology Therapeutics, Roswell Park Complete Cancer Center, New York, NY, USA; d German Cancer Analysis Center (DKFZ) and German Cancer Consortium (DKTK), Heidelberg, Germany, heidelberg, Germany; eDepartment of Pharmacology Therapeutics, Roswell Park Complete Cancer Center, New York, NY, USA; fi3S Instituto de Investiga o e Inova o em Sa e, Porto University, Portugal; IPATIMUP Instituto de Patologia e Imunologia Molecular da Universidade do Porto; FMUP Faculdade de Medicina da Universidade do Porto, Porto, Portugal; gGerman Cancer Analysis Center (DKFZ) and German Cancer Consortium (DKTK), Heidelberg, Germany, Heidelberg, Germany; hUniversity of Michigan Healthcare School, Ann Arbor, MI, USA.aIntroduction: EV released by tumours reaches target cells at distant websites. The study of their capture in vivo has been limited.
